"Protein biomarkers for COPD outcomes".
"Protein biomarkers for COPD outcomes".
Chest. 2021 Jan 09;:
Authors: Serban KA, Pratte KA, Bowler RP
Abstract
Chronic obstructive pulmonary disease (COPD) is a clinically heterogeneous syndrome characterized by injury to airways, airspaces and lung vasculature and usually caused by tobacco smoke and/or air pollution exposure. COPD is also independently associated with non-pulmonary comorbidities (e.g. cardiovascular disease) and malignancies (e.g. gastrointestinal and bladder), suggesting a role for systemic injury. Since not all those with exposure develop COPD, there has been a search for plasma and lung biomarkers that confer increased cross-sectional and longitudinal risk. This search typically focuses on clinically-relevant COPD outcomes such as forced expiratory volume at 1 second (FEV1), FEV1 decline, computer tomography (CT) measurements of emphysema, or exacerbation frequency. The rapid advances in omics technology and the molecular phenotyping of COPD cohorts now permit large-scale evaluation of genetic, transcriptomic, proteomic, and metabolic biomarkers. This review focuses on protein biomarkers associated with clinically-relevant COPD outcomes. The prototypic COPD protein biomarker is alpha-1 antitrypsin; however, this biomarker only accounts for 1-5% of COPD. This manuscript reviews and summarizes the evidence for other validated biomarkers for each COPD outcome, and discusses their advantages, weaknesses, and required...
Source: Chest - Category: Respiratory Medicine Authors: Serban KA, Pratte KA, Bowler RP Tags: Chest Source Type: research
More News: Alpha-1 Antitrypsin Deficiency | Cancer & Oncology | Cardiology | Cardiovascular | Chronic Obstructive Pulmonary | Computers | Emphysema | Gastroenterology | Genetics | Heart | Respiratory Medicine | Science | Smokers